- Conditions
- Lymphoma
- Interventions
- polyamine analogue PG11047
- Drug
- Lead sponsor
- Progen Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 644
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
- Drug · Other
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Rituximab, Obinutuzumab
- Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
- Interventions
- Nivolumab, Pomalidomide
- Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma
- Interventions
- CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 31 Days to 30 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
- Interventions
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
- Drug · Dietary Supplement
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- UCART19
- Biological
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- DLBCL, Neurotoxicity Syndromes
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Interventions
- Idasanutlin, Obinutuzumab, Venetoclax, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Chicago, Illinois • Louisville, Kentucky + 4 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- laromustine
- Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- beclomethasone dipropionate
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 5 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- fenretinide
- Drug
- Lead sponsor
- California Cancer Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Orange, California • Whittier, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
- Drug · Procedure · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies, Hematology, Leukemia, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Oncology Patients, T Cell Lymphoma, Tumors
- Interventions
- AMG 319
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 7
- States / cities
- Stanford, California • St Louis, Missouri • Columbus, Ohio + 4 more
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis
- Procedure · Radiation · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- C7R.CD30.CAR-EBVST cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, fludarabine phosphate, pixantrone dimaleate
- Biological · Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- vorinostat, isotretinoin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania